ZURICH--(BUSINESS WIRE)--Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that the European Medicines Agency (EMA) Name Review Group (NRG) and the Agency’s Committee for Human Medicinal Products (CHMP) has approved the company’s proposed trade name – SCENESSE® (pronounced “sen-esse”) – for its proprietary first-in-class medicinal photoprotective drug.
